Peptide Vendor Shutdowns 2025-2026: A Complete Timeline
A Market in Free Fall: The Vendor Shutdown Timeline
The research peptide vendor landscape between mid-2025 and mid-2026 experienced the most concentrated period of disruption in the industry’s history. Three of the largest US-based vendors exited the market — through regulatory enforcement, criminal prosecution, and voluntary closure — within a nine-month span. This timeline documents what happened, when it happened, and why it matters for researchers still navigating the aftermath.
June 2025: Amino Asylum — FDA Raid
On June 12, 2025, FDA agents conducted a physical raid on Amino Asylum’s operational facility. The raid — involving agents from the FDA’s Office of Criminal Investigations — resulted in the seizure of product inventory, manufacturing equipment, and business records. The company’s website went offline within hours and never returned.
Amino Asylum had been one of the largest US peptide vendors by product volume, known for aggressive pricing and a broad catalog that included both peptides and SARMs. The company operated from a physical facility rather than a dropship model, which made it vulnerable to the kind of physical enforcement action that purely online vendors can more easily evade.
The specific charges underlying the raid have not been fully disclosed in public court filings as of this writing. However, the involvement of the FDA’s criminal investigation division — rather than a civil compliance action — indicates the government treated Amino Asylum’s operations as potential criminal violations rather than regulatory non-compliance. The distinction matters: regulatory non-compliance typically results in warning letters and cease-and-desist orders, while criminal investigation can lead to felony charges, asset forfeiture, and imprisonment (Wikipedia: FDA enforcement).
The immediate market impact was significant. Amino Asylum’s customer base — estimated in the tens of thousands based on web traffic data and community discussion — was instantly displaced. Competing vendors reported surges in new customer registrations in the weeks following the raid, and community forums were flooded with questions about alternative suppliers.
December 2025: Paradigm Peptides — Guilty Pleas
On December 3, 2025, the founders of Paradigm Peptides entered guilty pleas to federal charges related to the sale of unapproved drugs. The case — prosecuted in the Northern District of Indiana — established criminal liability for peptide vendor operators and sent the clearest signal yet that the federal government views certain peptide sales as drug distribution rather than research chemical commerce.
Paradigm Peptides had positioned itself as a premium vendor with an emphasis on quality testing and customer service. The company’s website featured detailed COA documentation and educational content — a presentation that made its criminal prosecution particularly jarring for the researcher community. If Paradigm, with its apparent commitment to compliance, could face federal charges, the implication was that no vendor was immune from prosecution.
The legal theory underlying the Paradigm prosecution centered on the gap between marketing language and regulatory classification. The government’s position was that Paradigm’s products — despite “research use only” labeling — were marketed in ways that implied therapeutic use, effectively making them unapproved drugs under the Federal Food, Drug, and Cosmetic Act. Product descriptions mentioning specific biological effects, customer communications discussing protocols, and marketing materials referencing health outcomes were cited as evidence of drug marketing rather than research chemical sales.
The guilty pleas were significant because they established precedent without a trial. A conviction after trial would have been legally identical, but the guilty pleas meant the legal theory was never tested by a jury — it was accepted by the defendants as part of plea negotiations. Whether the same theory would survive a contested trial in a different jurisdiction remains an open question.
March 2026: Peptide Sciences — Voluntary Closure
Peptide Sciences — widely regarded as the gold standard of US research peptide suppliers for most of the 2020s — voluntarily ceased operations in March 2026. The company’s website went dark without a public explanation, and no regulatory enforcement action has been publicly linked to the shutdown.
The voluntary nature of the closure distinguishes it from the Amino Asylum and Paradigm exits. Peptide Sciences appears to have made a business decision to exit rather than being forced out. The timing — following both the Amino Asylum raid and the Paradigm prosecution — suggests a calculation that the regulatory risk of continued operation outweighed the business opportunity. This is speculation based on circumstantial evidence; the company has not publicly stated its reasons.
Peptide Sciences’ departure was the most consequential of the three exits for the broader market. The company had set the quality standard that other vendors were measured against — extensive COA documentation, independent quality verification, consistent delivery, responsive support. Its closure left a trust vacuum that the market is still attempting to fill eighteen months later (PubMed: Peptide supply chain research).
February 2026: FDA Reclassification — The Regulatory Backdrop
Between the Paradigm prosecution and the Peptide Sciences closure, the FDA took a separate regulatory action that further destabilized the market. In February 2026, the agency reclassified BPC-157, TB-500, and AOD-9604 as Category 1 compounds for compounding purposes, removing them from the list of substances eligible for pharmacy compounding under 503A and 503B exemptions.
This reclassification did not directly cause any vendor shutdown, but it intensified the regulatory uncertainty that was already driving exits. The message was clear: the FDA was actively reviewing peptide compounds, actively restricting access through the compounding pathway, and actively enforcing against vendors whose marketing crossed the line from research chemicals to therapeutic products.
The cumulative effect of the raid, the prosecution, the reclassification, and the voluntary closure was a market environment where operating a research peptide business carried visibly higher legal, regulatory, and financial risk than it had twelve months earlier.
April 2026: Warning Letters — The Line Gets Clearer
On April 2, 2026, the FDA issued warning letters to seven peptide vendors. All seven letters were dated March 31 and originated from the Center for Drug Evaluation and Research. The letters cited specific product page language as evidence of misbranding — product descriptions mentioning appetite suppression, weight loss, wound healing, muscle growth, and other therapeutic outcomes.
The warning letters were significant not for what they prohibited (therapeutic claims had always been prohibited) but for the specificity of the enforcement. The FDA identified exact phrases on exact product pages, demonstrating that the agency was actively reviewing vendor websites and documenting specific compliance failures. This was not a general policy statement — it was targeted, evidence-based enforcement against named companies.
For surviving vendors, the warning letters provided the clearest guidance yet on where the enforcement line sits. Product pages that describe what a peptide does in the human body — regardless of “research use only” disclaimers elsewhere — create regulatory exposure. Product pages that describe chemical properties, purity data, and storage requirements without therapeutic language remain on the compliant side of the line.
April–September 2026: The Enforcement Widens
The five months after the March warning letters brought no single shutdown on the scale of Peptide Sciences, but the pattern of enforcement broadened on every front — regulatory, criminal, civil, and commercial.
April 15 — Category 2 removals. FDA gave notice that it would remove twelve peptide bulk drug substances from Category 2 of its compounding list. Coverage at the time framed this as peptides being “legal again.” It was not: the substances came off the safety-concern list because their nominators withdrew the nominations, not because FDA cleared them. Removal from Category 2 is not placement on the approved bulks list, and the PCAC review that could lead there was still ahead.
June 17 — Wholesale Peptide. FDA’s Center for Drug Evaluation and Research issued a warning letter (reference 729447) to Wholesale Peptide of Brooksville, Florida, after a website review. The letter follows the March template: research-use labeling rejected, product descriptions cited as evidence of intended human use.
July — Paradigm Peptides sentencing. The Northern District of Indiana sentenced Paradigm’s two principals to 70 months and 16 months in federal prison, with a $5 million forfeiture. Founder Matthew Kawa admitted to forging laboratory certificates of analysis — the first public confirmation that a major vendor’s COAs were fabricated rather than merely unverified. The conduct ran from 2019 to 2024 and included products sold as SARMs that contained testosterone.
July — Strate Labs closed. One of several mid-tier vendors to exit without a public statement. Trade coverage through the summer also recorded the closures of Royal Research, Peptide Tech Labs, American Research Labs, and Unchained Compounds, bringing the count of vendor exits since mid-2025 to at least nine.
July 23–24 — PCAC vote. FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides and voted to recommend six — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for the Section 503A bulks list. Emideltide (DSIP) was rejected 6–7. The votes are advisory; HHS has not acted on them as of September, and FDA’s own scientific staff opposed several. If adopted, the six could be compounded by licensed pharmacies — a legal pathway that would reshape the research market for those specific compounds.
August 12 — Lilly’s payment-rail letter. Eli Lilly wrote to card networks, payment processors, buy-now-pay-later providers, and shippers asking them to stop serving vendors that sell retatrutide, naming six defendants in parallel federal suits. This opened a commercial front that does not depend on FDA at all: a vendor cut off by Stripe, Afterpay, or UPS is out of business regardless of its regulatory posture.
August 14 — Pure Rawz on maintenance. One of the largest surviving catalogs (69+ peptides, roughly $370,000 monthly revenue by prior estimates) replaced its storefront with a maintenance page carrying no products and no closure statement. As of this update it has not returned.
August 24 — five warning letters. FDA issued letters to Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners, and TXP Innovations (Tex Peptides), posted September 1. Each was triggered by a July website review. Each rejected research-use labeling. And each treated bacteriostatic water sold alongside peptides as a drug — the Peptide Partners letter called it “providing the means to prepare an injectable drug for human administration.” Our FDA warning letter tracker records the full detail of each.
Updated shutdown count
| Vendor | Date | How it ended |
|---|---|---|
| Amino Asylum | Jun 2025 | FDA raid; permanently offline |
| Paradigm Peptides | Dec 2025 (plea) / Jul 2026 (sentence) | Criminal prosecution; 70-month sentence, forged COAs admitted |
| Science.bio | Jan 27, 2026 | Announced closure |
| Peptide Sciences | Mar 6, 2026 | Voluntary closure; no enforcement action public |
| Royal Research | H1 2026 | Closed without statement |
| Peptide Tech Labs | H1 2026 | Closed without statement |
| American Research Labs | H1 2026 | Closed without statement |
| Unchained Compounds | H1 2026 | Closed without statement |
| Strate Labs | Jul 2026 | Closed without statement |
| Pure Rawz | Aug 14, 2026 | Maintenance page; status unknown |
Three different endings recur across this list — raid, prosecution, voluntary exit — and the distinction matters when a familiar name reappears. A storefront that revives under a closed brand should be treated as an unknown supplier until ownership and documentation are independently verified. Name continuity is not operator continuity.
The Post-Shutdown Market: What Filled the Vacuum
The demand displaced by three major vendor exits did not disappear — it redistributed. Several categories of suppliers moved to capture it.
Established mid-tier vendors with existing operations and quality records absorbed the most sophisticated customers — researchers who knew enough to evaluate alternatives and who prioritized operational history over marketing. These vendors generally maintained their existing quality standards and pricing while scaling operations to handle increased volume.
New entrants launched with aggressive marketing strategies designed to capture visibility quickly. PR-wire distributions, branded review-site networks, Google Shopping workarounds, and paid listicle placements created rapid brand awareness for vendors with little operational history. Some of these new entrants may prove to be legitimate long-term participants. Others are operating in the same regulatory gray areas that led to the exits they’re seeking to replace.
International suppliers — particularly Chinese manufacturers and European distributors — expanded their US-facing operations. These vendors offer competitive pricing driven by manufacturing-country cost advantages, but they introduce supply chain complexity (customs, shipping times, quality verification across jurisdictions) that domestic suppliers do not carry.
What Researchers Should Learn From the Timeline
The shutdown timeline teaches several lessons that remain relevant for vendor selection and research planning.
Vendor longevity is not guaranteed. Peptide Sciences operated for years as the default trusted supplier before closing voluntarily. Amino Asylum was shut down overnight by federal agents. Paradigm was prosecuted despite apparent compliance efforts. No vendor’s current existence guarantees its future existence, and researchers who depend on a single supplier for ongoing protocols carry concentration risk.
Marketing quality does not equal legal safety. Paradigm’s professional presentation — detailed COAs, educational content, responsive support — did not prevent federal prosecution. Vendors whose marketing looks sophisticated may face the same legal risks as vendors whose marketing looks amateur. The distinguishing factor is compliance posture, not production quality.
Regulatory risk is cumulative and directional. Each enforcement action has been more aggressive than the last — from warning letters to raids to criminal prosecution. The direction of regulatory engagement is consistently toward more enforcement, not less. Vendors operating in regulatory gray areas today face a narrowing window before those gray areas are resolved through enforcement (Wikipedia: Dietary supplement regulation).
Frequently Asked Questions
Is it still legal to buy research peptides after the vendor shutdowns?
Yes. The vendor shutdowns and prosecutions targeted sellers, not buyers. Purchasing research peptides for legitimate laboratory use remains legal in the United States. The enforcement actions focused on vendors whose marketing crossed the line from research chemical sales to drug distribution through therapeutic claims.
Could more vendors be shut down or prosecuted?
The regulatory trajectory suggests continued enforcement. The FDA has demonstrated willingness to issue warning letters, conduct raids, and pursue criminal charges against peptide vendors. Vendors whose marketing includes therapeutic claims or whose business practices resemble drug distribution face ongoing risk.
Did the shutdowns affect peptide quality or availability?
The closures disrupted supply for researchers who depended on specific vendors but did not reduce overall market availability. Surviving vendors and new entrants filled the supply gap. Quality variance has likely increased, however, because the market’s quality-standard-setter (Peptide Sciences) is no longer operating, and some new entrants have limited quality track records.
What should researchers do to protect their supply chain?
Diversify suppliers rather than depending on one vendor. Verify quality independently through third-party testing. Maintain buffer stock of critical compounds. Evaluate vendor compliance posture — particularly marketing language — as a proxy for regulatory risk. And plan for the possibility that any given vendor may exit the market with limited notice.
PeptideQuill provides independent research news and analysis. This content is for informational purposes only and does not constitute medical or legal advice.
